Literature DB >> 8647174

Inhibition of interleukin-6 synthesis in an animal model of septic shock by anti-C5a monoclonal antibodies.

U Höpken1, M Mohr, A Strüber, H Montz, H Burchardi, O Götze, M Oppermann.   

Abstract

The complement activation fragment C5a was recently shown to induce interleukin (IL)-6 synthesis by peripheral blood mononuclear cells. To understand better the role of C5a in cytokine regulation in vivo, we investigated the effects of complement depletion by cobra venom factor (CVF) or of anti-C5a monoclonal antibodies (mAb) on IL-6 generation in an animal model of septic shock. Complement-depleted pigs which were subsequently challenged with Escherichia coli generated significantly (p < 0.05) less IL-6 during the 6-h observation period than complement-sufficient controls. To address specifically the role of C5a in IL-6 regulation, we produced a C5a(57-74) peptide-specific mAb (T13/9) which neutralizes the bioactivity of porcine C5a. The mAb T13/9 does not cross-react with the precursor protein C5. The pretreatment of pigs with anti-C5a mAb T13/9 prior to the induction of sepsis resulted in a decrease of over 75% in serum IL-6 bioactivity compared to control animals (p < 0.0001). These results indicate a role for C5a in the modulation of IL-6 synthesis in Gram-negative bacteremia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647174     DOI: 10.1002/eji.1830260522

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  21 in total

1.  Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis.

Authors:  R F Guo; M Huber-Lang; X Wang; V Sarma; V A Padgaonkar; R A Craig; N C Riedemann; S D McClintock; T Hlaing; M M Shi; P A Ward
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

2.  The C5a receptor is expressed by human renal proximal tubular epithelial cells.

Authors:  R Zahedi; M Braun; R A Wetsel; B H Ault; A Khan; T R Welch; M Frenzke; A E Davis
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

Review 3.  Back to the future: antibody-based strategies for the treatment of infectious diseases.

Authors:  H Barbaros Oral; Cüneyt Ozakin; Cezmi A Akdiş
Journal:  Mol Biotechnol       Date:  2002-07       Impact factor: 2.695

Review 4.  Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS).

Authors:  Shreyas K Roy; Daniel Kendrick; Benjamin D Sadowitz; Louis Gatto; Kathleen Snyder; Joshua M Satalin; Lorne M Golub; Gary Nieman
Journal:  Pharmacol Res       Date:  2011-06-21       Impact factor: 7.658

5.  Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist.

Authors:  A J Strachan; I A Shiels; R C Reid; D P Fairlie; S M Taylor
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

6.  Mechanisms of enhanced lung injury during sepsis.

Authors:  B J Czermak; M Breckwoldt; Z B Ravage; M Huber-Lang; H Schmal; N M Bless; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

7.  C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells.

Authors:  A Fayyazi; R Sandau; L Q Duong; O Götze; H J Radzun; S Schweyer; A Soruri; J Zwirner
Journal:  Am J Pathol       Date:  1999-02       Impact factor: 4.307

Review 8.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

9.  Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage.

Authors:  M Fung; M Lu; H Fure; W Sun; C Sun; N Y Shi; Y Dou; J Su; X Swanson; T E Mollnes
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

10.  Manipulation of the complement system for benefit in sepsis.

Authors:  Peter A Ward; Ren-Feng Guo; Niels C Riedemann
Journal:  Crit Care Res Pract       Date:  2012-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.